The goal is to work with partners to bring our drugs to the national and international markets, especially to bring more affordable,high-quality biologic medicines to patients.
Our leading pipeline is a next generation of anti-IgE antibody (LP-003), which is already in Phase III study, and prepare for BLA in 2025. The second leading pipeline is a bifunctional complement inhibitor (LP-005) , which is in Phase II at present.
Dr Sun, Bill Nai-chau co-founded Longbio in 2018. He is also a member of the Board at present.
Dr. Sun boasts a distinguished career as a serial entrepreneur, marked by numerous successes. Notably, he co-founded Tanox Inc. in 1986 and led its R&D department. Tanox, a biotech company based in Houston, US, went public on Nasdaq in 2000. In a significant milestone, the company was acquired by Genentech in 2006 for a staggering sum of 919 million USD. During his tenure at Tanox, Dr. Sun served as the main inventor behind the groundbreaking first-generation anti-IgE antibody, Omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic diseases. Since its listing over two decades ago, Omalizumab has amassed cumulative sales revenue exceeding 30 billion USD, with annual revenues still surpassing 4 billion USD.
Prior to his involvement with Longbio, Dr. Sun held the position of Founder and President at Xuhua, a drug discovery company in China, starting from 2001. Under his leadership, Xuhua collaborated on several innovative drug projects with listed companies in China, including the successful approval of Benegrastim (marketed as Ryzneuta®) by the US FDA and China NMPA in 2023.
Dr. Sun's early career included research roles at Oak Ridge National Laboratory and the National Cancer Institute. He earned his Ph.D. from Iowa State University.
Dr. Liu, Heng co-founded Longbio in 2018 and currently holds the positions of CEO and member of the Board.
Prior to his involvement with Longbio, Dr. Liu served as the Director of Pre-clinical and CMC at Generon from 2010 to 2017. During his tenure, he played a pivotal role in leading and participating in the development of several innovative drugs in both China and the United States. Notably, Dr. Liu deeply contributed to the development of a long-acting G-CSF (marketed as Benegrastim, Ryzneuta®), which successfully completed phase III clinical trials in both countries and received market approval from the US FDA and China NMPA.
Before joining Generon, Dr. Liu held the position of Director of R&D at HD Biosciences, which was later acquired by Wuxi AppTec, the largest Contract Research Organization (CRO) company in China.
Dr. Liu earned his Ph.D. from the State University of New York Downstate Medical Center.